Thomas Saugnac

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland.